CN107468625A - A kind of EGF for medical cosmetology imports liquid - Google Patents
A kind of EGF for medical cosmetology imports liquid Download PDFInfo
- Publication number
- CN107468625A CN107468625A CN201610401832.3A CN201610401832A CN107468625A CN 107468625 A CN107468625 A CN 107468625A CN 201610401832 A CN201610401832 A CN 201610401832A CN 107468625 A CN107468625 A CN 107468625A
- Authority
- CN
- China
- Prior art keywords
- egf
- effect
- cell
- cosmetology
- medical cosmetology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 21
- 230000008676 import Effects 0.000 title claims abstract description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 6
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 5
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 5
- 239000011570 nicotinamide Substances 0.000 claims abstract description 5
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 5
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 5
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 5
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 5
- 241000238582 Artemia Species 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 14
- 239000000843 powder Substances 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 241001247197 Cephalocarida Species 0.000 abstract 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 39
- 210000003491 skin Anatomy 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 12
- 210000001339 epidermal cell Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 206010040925 Skin striae Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002570 interstitial cell Anatomy 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/882—Mixing prior to application
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to care tool technical field, more particularly to a kind of EGF for medical cosmetology to import liquid.The invention discloses a kind of EGF for medical cosmetology to import liquid, it is characterised in that including following components and percentage by weight：Niacinamide:1 5%, xanthans:0.1 0.15%, Sodium Polyacrylate:0.2 0.25%, hyaluronic acid:0.05 0.3%, artemia extract:0.5 2%, remaining is water.The beneficial effects of the invention are as follows：EGF freeze-dried powders can be dissolved well, can mutually be cooperateed with EGF effect, reach the effect of multiple skin care, can effectively help absorbing for EGF, itself can also effectively strengthen EGF cosmetology effect.
Description
Technical field
The invention belongs to care tool technical field, more particularly to a kind of EGF for medical cosmetology to import liquid.
Background technology
It is current on the market for medical cosmetology by many makeups product, but such makeups product are being constantly present the problem of more during use.At present, experimental study shows hEGF（Epidermal
Growth Factor, EGF）It is a kind of small peptide of human body cell secretion, is made up of 53 amino acid residues, the dalton of molecular weight 6201, the disulfide bond that intramolecular is made up of 6 cysteines, form 3 intramolecular ring type structures, forms receptorbinding region necessary to bioactivity.EGF can stimulate skin histology, cornea and the growth and breeding of tracheal epithelial tissue, accelerate the reparation of cornea, the superficial wound such as skin, promote application on human skin epithelial cell, corneal epithelial cell and mammalian epithelial cell growth, strengthen the protein of epidermal cell cell, DNA and RNA synthesis and metabolism.
EGF plays physiological action by being combined with EGF receptor on cell membrane.Research shows：All contain EGF receptor, wherein epidermal cell content highest on the cell membrane of the various kinds of cell such as epidermal cell, fibroblast, endothelial cell and smooth muscle cell.EGF is combined with the EGF receptor on cell membrane, is passed the signal along to cell interior by enzyme cascade, is promoted the expression of the albumen associated with cell division, so as to promote cell growth to breed, accelerates cell metabolism.The combination of EGF and cell receptor has the sensitiveness of height, only needs the EGF of denier and can promote cell that above-mentioned biochemical reactions occur.
EGF has extensive biological effect, can strongly promote various epidermal tissues to grow, and medically oneself is used for the treatment of burn and scald, ulcer, all kinds of wounds and corneal injury etc..EGF can also promote the metabolism of normal epidermis cell, and whitening, crease-resistant, anti-aging can be haveed the function that by being added in cosmetics and skincare product.
Restructuring EGF is protein product, and to keep its bioactivity, the form of freeze-dried powder is typically all made by manufacturer.Wiped so needing and forming the liquid that can be smeared after a kind of importing liquid can dissolve to EGF.
The content of the invention
It is an object of the invention to solve the problems, such as techniques discussed above, there is provided one kind can dissolve to EGF freeze-dried powders well, can mutually it be cooperateed with EGF effect, reach the effect of multiple skin care, absorbing for EGF can effectively be helped, the EGF for medical cosmetology that itself can also effectively strengthen EGF cosmetology effect imports liquid, and its technical scheme is as follows：
A kind of EGF for medical cosmetology imports liquid, it is characterised in that including following components and percentage by weight：
Niacinamide: 1-5%,
Xanthans:0.1-0.15%,
Sodium Polyacrylate:0.2-0.25%,
Hyaluronic acid:0.05-0.3%,
Artemia extract:0.5-2%, remaining is water.
Preferred embodiment is, in addition to dipotassium glycyrrhizinate：0.05-0.3%, Aloe Vera Gel：1-10%.
Liquid is imported provided by the present invention for the EGF of medical cosmetology, when in use, it is only necessary to importing liquid is poured into EGF freeze-dried powders, then carries out rocking and uniformly enters to use.It can be applied in face and body.
Add dipotassium glycyrrhizinate：0.05-0.3%, Aloe Vera Gel：1-10%, it can cause this product that there is different functions, whitening and anti-aging function.
EGF mainly has in purposes cosmetically：
1st, tender skin effect
EGF can irritate various cells such as corneal epithelium and endothelial cell, epidermis, corium confluent monolayer cells (such as fibroblast), mammary gland alveolus and the interstitial cell of ectoderm and endodermal origin, make its proliferation apoptosis, accelerate metabolism, reach the effect of tender skin.
2nd, skin care
EGF can promote the biosynthesis of DNA, RNA and functional protein, can promote the synthesis (such as hyaluronic acid, elastomer albumen) of extracellular macromolecular, increase moisture content of skin, and then increase skin elasticity, Glycerin.
3rd, smooth away wrinkles
EGF, which promotes cytotrophy material to be transported to from extracellular active, into the cell, increases intracellular nutrition.Promote the functional moleculars such as corium confluent monolayer cells secretion synthesis collagenous fibres, polysaccharide, glycoprotein, make that subcutaneous dermal tissue is full, muscle fibre marshalling is close, so as to reduce and smooth away wrinkles.
4th, wound is repaired
Epidermal cell is irritated by being combined with EGF receptor（Epithelial cell including Various Tissues source, various interstitial cells）Into CDC, some interior critical function gene activations of active cell, expression, secretion biological activity protein etc..It is in the linear alignment, the growth of epidermal cell fast regular and timely flap coverage to promote collagenous fibres.After significantly accelerated beauty, cosmetic operation and the wound healing such as other skin traumas, and surface of a wound flat smooth is kept, abnormal pigmentary deposit on the skin trace is reduced or is disappeared and reduce pigmentation.
5th, color spot is prevented
EGE has stronger facilitation to the propagation of epidermal cell, use rear youthening of epidermal cell, so that less residual for having pigment and dead cell etc. is accumulated in epidermal tissue, make cutaneous manifestations go out it is tender have no time in vain, eliminate the abnormal skin such as color spot and pigmentation and show.The recurrence of color spot can effectively be contained using EGF in the treatment phase of nti-freckle and convalescence.
Restructuring EGF is protein product, and to keep its bioactivity, the form of freeze-dried powder is typically all made by manufacturer, when in use, uses importing liquid（Solvent）Dissolved and then use it for face.Because EGF is large biological molecule, it is difficult to reach skin corium through skin to play its bioactivity, so can the composition that import liquid be efficiently absorbed to utilize to EGF and play critical effect, in addition, skin care ingredient is suitably added in liquid is imported, it can mutually be cooperateed with EGF effect, reach the effect of multiple skin care.Therefore its composition of this product can effectively help absorbing for EGF, in addition, the skin care moisturizing composition of the importing liquid can also effectively strengthen EGF cosmetology effect.
The beneficial effects of the invention are as follows：EGF freeze-dried powders can be dissolved well, can mutually be cooperateed with EGF effect, reach the effect of multiple skin care, can effectively help absorbing for EGF, itself can also effectively strengthen EGF cosmetology effect.
Embodiment
Embodiment is specifically described below：
Embodiment 1：
A kind of EGF for medical cosmetology imports liquid, it is characterised in that including following components and percentage by weight：
Niacinamide: 1%,
Xanthans:0.1%,
Sodium Polyacrylate:0.2%,
Hyaluronic acid:0.05%,
Artemia extract:0.5%,
Also include dipotassium glycyrrhizinate：0.05%, Aloe Vera Gel：1%, remaining is water.
Embodiment 2：
A kind of EGF for medical cosmetology imports liquid, it is characterised in that including following components and percentage by weight：
Niacinamide: 5%,
Xanthans:0.15%,
Sodium Polyacrylate:0.25%,
Hyaluronic acid:0.3%,
Artemia extract:2%,
Also include dipotassium glycyrrhizinate：0.3%, Aloe Vera Gel：10%, remaining is water.
This product dispel striae of pregnancy experiment：
After person on probation cleans skin of abdomen sooner or later daily, the EGF freeze-dried powders of 20,000 active units of liquid dissolving are imported with 5ml, then the importing liquid is uniformly applied to belly, it is divided to two angels to be finished, after persistently using 60 days, the effectiveness and reliability of product, evaluation criteria are evaluated：Striae of pregnancy disappears or partial disappearance is effective, and striae of pregnancy does not disappear to be invalid；There is pruitus in belly, red and swollen, pimpling, pimple and other allergic symptoms for adverse reaction, otherwise to have no adverse reaction.
Total test total number of persons 200, striae of pregnancy eliminate efficiently individual quantity 196, the invalid people of number 4, and effective percentage reaches 98%；
Total test total number of persons 200, adverse reaction number 2, the invalid people of number 196, adverse reaction effective percentage 1%.
Claims (2)
1. a kind of EGF for medical cosmetology imports liquid, it is characterised in that including following components and percentage by weight：
Niacinamide:
1-5%,
Xanthans:0.1-0.15%,
Sodium Polyacrylate:0.2-0.25%,
Hyaluronic acid:0.05-0.3%,
Artemia extract:0.5-2%, remaining is water.
2. the EGF for medical cosmetology imports liquid as claimed in claim 1, it is characterised in that also including dipotassium glycyrrhizinate：0.05-0.3%, Aloe Vera Gel：1-10%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610401832.3A CN107468625A (en) | 2016-06-08 | 2016-06-08 | A kind of EGF for medical cosmetology imports liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610401832.3A CN107468625A (en) | 2016-06-08 | 2016-06-08 | A kind of EGF for medical cosmetology imports liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107468625A true CN107468625A (en) | 2017-12-15 |
Family
ID=60594556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610401832.3A Pending CN107468625A (en) | 2016-06-08 | 2016-06-08 | A kind of EGF for medical cosmetology imports liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107468625A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120478193A (en) * | 2025-07-21 | 2025-08-15 | 中山中研化妆品有限公司 | CGE repairing composition after medical and artistic treatment and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926741A (en) * | 2010-04-02 | 2010-12-29 | 广东雅倩化妆品有限公司 | Skin activating essence and skin care products containing the activating essence |
| CN102058504A (en) * | 2009-11-11 | 2011-05-18 | 日本乐敦制药株式会社 | Anti-saccharification agent |
| CN104721129A (en) * | 2015-04-13 | 2015-06-24 | 上海东晟源日化有限公司 | Microemulsion biotechnology skin care product |
| CN105193694A (en) * | 2015-10-29 | 2015-12-30 | 桂林华诺威基因药业有限公司 | Skin care product with whitening and freckle-removing functions |
-
2016
- 2016-06-08 CN CN201610401832.3A patent/CN107468625A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058504A (en) * | 2009-11-11 | 2011-05-18 | 日本乐敦制药株式会社 | Anti-saccharification agent |
| CN101926741A (en) * | 2010-04-02 | 2010-12-29 | 广东雅倩化妆品有限公司 | Skin activating essence and skin care products containing the activating essence |
| CN104721129A (en) * | 2015-04-13 | 2015-06-24 | 上海东晟源日化有限公司 | Microemulsion biotechnology skin care product |
| CN105193694A (en) * | 2015-10-29 | 2015-12-30 | 桂林华诺威基因药业有限公司 | Skin care product with whitening and freckle-removing functions |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120478193A (en) * | 2025-07-21 | 2025-08-15 | 中山中研化妆品有限公司 | CGE repairing composition after medical and artistic treatment and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101678621B1 (en) | Composition comprising spicules for skin care | |
| CN113301910B (en) | Skin rejuvenation and healing mixtures of peptide components and uses thereof | |
| JP5814177B2 (en) | Plant-derived elastin-binding protein ligand and method of use thereof | |
| CA2846382C (en) | Manganese based compounds for elastogenesis and connective tissue treatment | |
| CN104784071B (en) | A kind of comprehensive anti-aging water-setting dew of skin and preparation method thereof | |
| KR102613845B1 (en) | Cosmetic composition for improvement of skin derived from natural products | |
| CN101785852A (en) | Dermis trace intervention anti-wrinkle cosmetic preparation and method | |
| DK2699249T3 (en) | cartilage Product | |
| CN101884602A (en) | A kind of cosmetic formulations of skin-care, defect-repairing, anti-aging and winkle-removing | |
| CN103948525B (en) | Anti-aging active composition for epidermis | |
| CN102078266A (en) | a cosmetic composition | |
| Abd Samad et al. | Collagen: New dimension in cosmetic and healthcare | |
| CN106691923B (en) | Composition and preparation for cosmetic repair, and preparation method and application thereof | |
| KR20150120426A (en) | Cosmetic composition containing a brown alga extract, a yeast extract and ascorbic acid | |
| CN110478306A (en) | Facial mask of the culture supernatant containing placenta mesenchyma stem cell and preparation method thereof | |
| CN110585111A (en) | Anti-aging cosmetic additive and preparation method thereof | |
| CN104887542A (en) | Cosmetic composition | |
| CN103520017A (en) | Wrinkle-removing, anti-ageing, skin-activating, restoring and whitening composition | |
| CN110882177A (en) | Skin repair oligopeptide composition and preparation method thereof | |
| CN106344435A (en) | Skin protection cream capable of eliminating striae gravidarum | |
| CN104323966A (en) | Golden hydrotherapy composition and using method thereof | |
| CN107468625A (en) | A kind of EGF for medical cosmetology imports liquid | |
| CN103690393A (en) | Skin-whitening anti-wrinkle biological silk mask | |
| CN107551262A (en) | It is a kind of that there is anti-ageing, wrinkle removing effect formulation product | |
| CN105727252A (en) | Nursing composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171215 |
|
| RJ01 | Rejection of invention patent application after publication |